These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 31393884)
41. The Canadian multicentre study of deep brain stimulation for cervical dystonia. Kiss ZH; Doig-Beyaert K; Eliasziw M; Tsui J; Haffenden A; Suchowersky O; ; Brain; 2007 Nov; 130(Pt 11):2879-86. PubMed ID: 17905796 [TBL] [Abstract][Full Text] [Related]
42. Automated assessment of cervical dystonia. Galardi G; Micera S; Carpaneto J; Scolari S; Gambini M; Dario P Mov Disord; 2003 Nov; 18(11):1358-67. PubMed ID: 14639682 [TBL] [Abstract][Full Text] [Related]
43. Development and Validation of a Disease-Specific Oromandibular Dystonia Rating Scale (OMDRS). Yoshida K Front Neurol; 2020; 11():583177. PubMed ID: 33224096 [No Abstract] [Full Text] [Related]
44. Objective assessment of cervical dystonia: a pilot study. Zetterberg L; Halvorsen K; Färnstrand C; Lundström E; Lindmark B; Aquilonius SM Acta Neurol Scand; 2005 Oct; 112(4):248-53. PubMed ID: 16146495 [TBL] [Abstract][Full Text] [Related]
45. A pilot study of botulinum toxin A for headache in cervical dystonia. Ondo WG; Gollomp S; Galvez-Jimenez N Headache; 2005 Sep; 45(8):1073-7. PubMed ID: 16109123 [TBL] [Abstract][Full Text] [Related]
46. Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia. Figgitt DP; Noble S Drugs; 2002; 62(4):705-22. PubMed ID: 11893235 [TBL] [Abstract][Full Text] [Related]
47. [A double-blind comparative study to evaluate the efficacy and safety of NerBloc® (rimabotulinumtoxinB) administered in a single dose to patients with cervical dystonia]. Kaji R; Shimizu H; Takase T; Osawa M; Yanagisawa N Brain Nerve; 2013 Feb; 65(2):203-11. PubMed ID: 23399677 [TBL] [Abstract][Full Text] [Related]
49. Cervical dystonia and quality of life. Tomic S; Petkovic I; Pucic T; Resan B; Juric S; Rotim T Acta Neurol Belg; 2016 Dec; 116(4):589-592. PubMed ID: 27138215 [TBL] [Abstract][Full Text] [Related]
50. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Brashear A; Lew MF; Dykstra DD; Comella CL; Factor SA; Rodnitzky RL; Trosch R; Singer C; Brin MF; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M Neurology; 1999 Oct; 53(7):1439-46. PubMed ID: 10534248 [TBL] [Abstract][Full Text] [Related]
51. Reliability and validity of the range of motion scale (ROMS) in patients with abnormal postures. van Rooijen DE; Lalli S; Marinus J; Maihöfner C; McCabe CS; Munts AG; van der Plas AA; Tijssen MA; van de Warrenburg BP; Albanese A; van Hilten JJ Pain Med; 2015 Mar; 16(3):488-93. PubMed ID: 25220173 [TBL] [Abstract][Full Text] [Related]
52. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Truong D; Brodsky M; Lew M; Brashear A; Jankovic J; Molho E; Orlova O; Timerbaeva S; Parkinsonism Relat Disord; 2010 Jun; 16(5):316-23. PubMed ID: 20359934 [TBL] [Abstract][Full Text] [Related]
54. Predictive factors of outcome in primary cervical dystonia following pallidal deep brain stimulation. Witt JL; Moro E; Ash RS; Hamani C; Starr PA; Lozano AM; Hodaie M; Poon YY; Markun LC; Ostrem JL Mov Disord; 2013 Sep; 28(10):1451-5. PubMed ID: 23787946 [TBL] [Abstract][Full Text] [Related]
55. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial. Pappert EJ; Germanson T; Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274 [TBL] [Abstract][Full Text] [Related]
56. Automated Quantification of the Landing Error Scoring System With a Markerless Motion-Capture System. Mauntel TC; Padua DA; Stanley LE; Frank BS; DiStefano LJ; Peck KY; Cameron KL; Marshall SW J Athl Train; 2017 Nov; 52(11):1002-1009. PubMed ID: 29048200 [TBL] [Abstract][Full Text] [Related]